Delivering Life-Changing Therapies to Patients
Mission and Vision

To be a **global** biopharmaceutical company delivering **life-changing therapeutics** built upon a foundation in China
**Visionary Management Team**

Thought leaders and political influencers directly involved in shaping the future of China’s orphan drug market

**Pioneer in China’s Orphan Drug Market**

**Leadership:** Sole Deputy Director General from industry for China’s Alliance for Rare Disease (CARD)

**Experience:** CANbridge Team launched first rare disease drug in China

**Balanced Business Model**

**Foundation:** Leverage near term revenue from oncology to support orphan drug development

**Future:** The premier partner for China and global rare disease drug development

**Deep, Advanced Portfolio**

**Portfolio:** 1 marketed, 2 near-commercial, 5 rare disease and 2 oncology clinical candidates

**De-risked:** Most candidates target commercially validated pathways

**Leverage Technology Partnerships**

**Strategy:** Partner with leading academic institutions and biopharma companies

**Execution:** Partnership with Wuxi and GC Pharma to prosecute product candidates in China

**Comprehensive Global Solution Provider**

**Mission:** To be a global biopharmaceutical company delivering life-changing therapeutics built upon a foundation in China

**Investment Highlights**

- **Deep, Advanced Portfolio**
  - 1 marketed, 2 near-commercial, 5 rare disease and 2 oncology clinical candidates
  - Most candidates target commercially validated pathways

- **Mission:** To be a global biopharmaceutical company delivering life-changing therapeutics built upon a foundation in China

- **Leadership:** Sole Deputy Director General from industry for China’s Alliance for Rare Disease (CARD)

- **Experience:** CANbridge Team launched first rare disease drug in China
# World Class Leadership Team with Deep Experience

**James Xue, Ph.D., M.B.A**  
Founder, Chairman, Chief Executive Officer

- A veteran entrepreneur with extensive experience from small biotech to multi-national biopharmaceutical companies across the US and China
- Managed the launch of several life-saving drugs for the treatment of hematologic cancer and rare metabolic diseases in China including Thymoglobuline® and Cerezyme®
- Founding member and sole Deputy Director General of China’s Alliance for Rare Disease (CARD)
- R&D Committee Member of China Pharmaceutical Innovation and Research Development Association (PHIRDA)
- Member of Advisory Committee of Joint Institute of Peking University Health Science Center and University of Michigan Medical School

**Ben Wu, M.B.A**  
Head of Rare Disease Business

- Brings significant orphan drug experience from across Asia
- Joined Genzyme in 2008 to pioneer the company’s efforts to expand rare disease business into Hong Kong; held various management positions covering Southeast Asia, Taiwan and China; Spent 14 years at JNJ where he held various leadership positions

**Fangzhou Cheng**  
VP of China BU Head

- Brings 18 years of China MNC oncology sales and marketing and commercial management experience
- Previously Senior Director and China Oncology BU Head of Celgene; Sales Director at Pfizer China; and member of Iressa marketing team at AstraZeneca China

**Glenn Hassan**  
CFO and CBO

- More than 15 years experience in the healthcare sector globally, as an investor, investment banker, and strategy consultant.
- Previously, Director of Investment Banking at China Renaissance; Portfolio Manager and Senior Analyst at Leerink Capital; Senior Therapeutic Analyst at Citadel’s Surveyor Capital; Senior Healthcare Specialist at Fidelity Management & Research Company

**Gerald Cox, M.D., Ph.D.**  
Chief Development Strategist and Acting Chief Medical Officer

- Previously Chief Medical Officer at Editas Medicine; Vice President of Clinical Development, Rare Disease at Sanofi Genzyme
- Staff Physician in Genetics at Boston Children’s Hospital and Instructor in Pediatrics at Harvard Medical School since 1994
- Led the global clinical development of new treatments and world-wide approvals of Aldurazyme® (laronidase), Cerdelga® (eliglustat), and Elaprase® (idursulfase) in Japan

**James Geraghty, Ph.D.**  
Board Director

- Industry leader with 30 years of strategic and leadership experience
- Previously, North America Strategy and BD at Sanofi; 20 years at Genzyme, where his roles included SVP of International Development, President of Genzyme Europe, and General Manager of Genzyme’s cardiovascular business
- Board member of Orchard, Idera, etc
## Pipeline Overview

<table>
<thead>
<tr>
<th>Field</th>
<th>Compound</th>
<th>Indication</th>
<th>Pre-clinical</th>
<th>Ph I</th>
<th>Ph II</th>
<th>Ph III</th>
<th>Marketed</th>
<th>License Partner</th>
<th>License Country</th>
<th>Estimated China Prevalence</th>
<th>Milestones/Development Path</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare Disease</td>
<td>CAN 101²</td>
<td>MPS II³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>GCPharma</td>
<td>Greater China³</td>
<td>1 per 166,000</td>
<td>2H 2019 – NDA Submission (China) / 1H 2020 NDA Approval</td>
</tr>
<tr>
<td></td>
<td>CAN 106</td>
<td>Complement Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>WuXi Biologics</td>
<td>Greater China³</td>
<td>Varies</td>
<td>1H 2020 – IND (China) Application</td>
</tr>
<tr>
<td></td>
<td>CAN 103</td>
<td>Lysosomal Storage Disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>WuXi Biologics</td>
<td>Global</td>
<td>1 per 100,000</td>
<td>2H 2019 – IND (China) Application</td>
</tr>
<tr>
<td></td>
<td>CAN 105</td>
<td>Hemophilia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>WuXi Biologics</td>
<td>Greater China³</td>
<td>3 per 100,000</td>
<td>1H 2021 – IND (China) Application</td>
</tr>
<tr>
<td></td>
<td>CAN 104</td>
<td>Lysosomal Storage Disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>WuXi Biologics</td>
<td>Global</td>
<td>1 per 40,000</td>
<td>2H 2020 – IND (China) Application</td>
</tr>
<tr>
<td></td>
<td>CAN 107</td>
<td>Metabolic Disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>WuXi Biologics</td>
<td>Greater China³</td>
<td>4 per 100,000</td>
<td>2H 2020 – IND (China) Application</td>
</tr>
<tr>
<td></td>
<td>CAN 002</td>
<td>Oral Mucositis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CUSA Pharma</td>
<td>China</td>
<td>22.30% Of Cancer Patients</td>
<td>Marketed</td>
</tr>
<tr>
<td>Oncology</td>
<td>CAN 030</td>
<td>HER2+ Breast Cancer Extended Adjuvant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>WuXi Biologics</td>
<td>Greater China³</td>
<td>20.30% Of Breast Cancer Patients</td>
<td>2H 2019 / 1H 2020 NDA (China) Approval</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HER2+ Metastatic Breast Cancer &gt;=2nd line</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>WuXi Biologics</td>
<td>Greater China³</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CAN 008</td>
<td>Glioblastoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Apogenix</td>
<td>Greater China³</td>
<td>2 per 100,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CAN 017</td>
<td>Esophageal Squamous Cell Carcinoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AVEO Oncology</td>
<td>Global (exclude North America)</td>
<td>22 per 100,000</td>
<td></td>
</tr>
</tbody>
</table>

1 MPS II refers to Mucopolysaccharidosis type II; 2 CAN 101 is currently being marketed outside of China; 3 Greater China includes China, Hong Kong, Taiwan and Macau; 4 NCBI Website
Rare Disease Pipeline
China Rare Disease Market:
Large and Untapped Opportunity

The market potential for rare disease drugs in China is estimated to be 35-40% of the US market.

2. As a reference: 17 oncology drug gain national reimbursement listing with 55% price reduction on average (Oct 2018)
3. Assume only 20% of China’s population have access to proper diagnosis & treatment access (compared to 58% Urban Population)
4. \[(400\% \times 45\% \times 20\%) = 36\% \]
5. \[36\% \times \text{US Orphan Drug Market $43 Billion in 2017 (Quintile IMS Orphan Drugs in US Oct 2018 Report)}\]
Some Cities and Provinces Have Reimbursed Rare Disease Products (Cerezyme Case Study)
Reaching Tipping Point for Rare Diseases in China

2018
- **May 11, 2018**
  - First National Rare Disease List (121 diseases)
- **May 23, 2018**
  - Acceptance for overseas clinical data for treatment of seriously life-threatening and rare diseases
- **July 10, 2018**
  - Priority review Drugs for rare and pediatric diseases can be considered by CDE
- **Nov 1, 2018**
  - Expedited review
    - NMPA releases a list of 48 much needed new orphan drugs marketed outside China

2019
- **Oct 24, 2018**
  - China Alliance for Rare Diseases (CARD) inauguration, the first cross disciplinary alliance for policy advocacy in China
- **March 13, 2019**
  - Establish annual dynamic adjustment mechanism for NRDL; 2019 NRDL renewal to be completed by Sep 2019, and rare disease is specifically highlighted for reimbursement change

2018 is a breakthrough year in China for the acceleration and advancement of addressing treatment for rare disease, 2019 is shaping up to be the implementation year
Unique Approach to Rare Diseases in China

Leverage China-rooted Relationships to...

- Access abbreviated regulatory development pathways including Clinical Trial Waivers (CTW)
- Coordinate directly with China authorities to provide China government “one-stop shop” with predictable exposure to rare disease healthcare expenditures
- Support development of Centers of Excellence

Pioneer China Orphan Drug Access

- Establish strong provincial level market access team to drive reimbursement process on the local level
- Reinvest profits into R&D research and development locally to build the first real innovative rare disease company in China and further strengthen government relationships
CAN 101 (Hunterase) Overview

Enzyme Replacement Therapy (ERT)

**Indication:** MPS II – lysosomal storage disease, X-linked recessive disorder  
**Development Status:** Filing China NDA by Q219, already marketed outside of China

### Significant Unmet Needs
- MPS II is listed on National Rare Disease List
- 5,000 – 6,000 patients in China\(^1,2\)

### Potential Differentiation
- Less anticipated AEs
- Better potential efficacy

### Strategic Value
**First potential commercial asset for CANbridge Rare Disease Portfolio**
- High unmet need, No treatment available in China
- ERT is standard of care for MPS II

\(^1\) Khan et al, 2017  
\(^2\) Orphanet
CAN 101 - Phase I/II Clinical Study Result

CAN101 significantly reduced percent change in urine GAG compared to Elaprase®.

![](chart1.png)

CAN101 significantly increased percent change in 6-MWT compared to Elaprase®.

![](chart2.png)

* T-test (<0.05, Statistically significant)
† ANCOVA(<0.05, Statistically significant)
†† ANCOVA(<0.01, Statistically significant)
CAN 101 Pre-Launch Preparation
Focusing on Key Cities and Provinces

Prioritization Criteria

Financial Capabilities
Socioeconomic Status
Rare Disease Experts
Patient # & Advocacy
Funding Mechanism
CAN 106 Overview

**Monoclonal Antibody**

**Indication:** Complement-Mediated Diseases – multiple indications

**Development Status:** Preclinical, with potential IND submission in 1H 2020

**Significant Unmet Needs**

Eculizumab is approved but not yet launched

**Potential Differentiation**

- Potential lower production costs
- Potentially similar half-life and better efficacy vs. 2nd Gen Anti-C5

**Strategic Value**

- CANbridge has China rights with ROFN for global rights to develop & commercialize this new molecular entity
- Strategic collaboration with WuXi Biologics (2269. HK), a leading global open-access biologics technology platform company
- Carries high franchise value; One of the most expensive and largest rare disease products globally
Global Opportunity to Serve Unmet Medical Needs

- Complement plays important role in multiple rare diseases due to its function in inflammatory and cell killing processes.
- Globally, patients still have limited access to modern therapy, due to its high cost.
- $4bn market today$^2$; there is room for another player to enter with only one player currently on the market.
- China still represents the largest untapped market.

---

$^1$ Risitanon and Rotoli, 2008 & Chinese KOL interview; China aHUS Diagnosis and Treatment Consensus, 2017; China MG Diagnosis and Treatment Guideline, 2015 & Howard et al, 2017; Zanella and Barcellini, 2014 & Berentsen and Sundic, 2015; Mahmoud et al, 2016

$^2$ Jefferies research
**CAN 103 Overview**

**Enzyme Replacement Therapy (ERT)**

**Indication:** Gaucher Disease – rare, progressive, metabolic, genetic disorder  
**Development Status:** Preclinical, produced by using recombinant DNA technology

---

**Significant Unmet Needs**

- **13,000-15,000** patients in China\(^1,2\)
- >95% of patients without access to specialized treatment

**Potential Differentiation**

- Lower Production Costs  
- Potentially better efficacy

---

**Strategic Value**

- CANbridge has global proprietary rights to develop & commercialize this new molecular entity  
- Strategic collaboration with WuXi Biologics (2269. HK), a leading global open-access biologics technology platform company  
- Carries high franchise value; One of the best known and prototypical Rare Diseases in China

---

1. Burrow et al, 2011; 2. Orphanet
Additional Opportunities in BD Pipeline

- Potential Additional Programs from Wuxi Biologics
- Portfolio Deal
- Gene Therapy and Cell Therapy
Oncology Pipeline
CANbridge Oncology Strategy

**Leverage Partnerships**
In-license late stage de-risked assets from established biopharma companies

**Portfolio Strategy**
Target Chinese high-prevalent indications with poor outcome due to lack of western standard of care; leverage existing commercial infrastructure

**Smart Clinical Design and Regulatory Strategy**
- Biomarker-targeted patient population, smaller trial size
- Shortened time-to-market enabled by global data and expedited approval pathway

**Commercial and Market Access**
- Low risk in revenue ramp up, driven by treatment superiority and high unmet needs in China market
- Target adjacent areas to current oncology portfolio
CAN 030 (Nerlynx) Strategic Potential

**Nerlynx® / Neratinib**

Pan-HER tyrosine kinase inhibitor, irreversible inhibition

**Development Status:** Potential for China NDA approval 1H2020

---

### Strategic Value

- More than 300K new breast cancer patients in China in 2018\(^1\),\(^2\); One of six most prevalent cancers and the most common cancer in women in China
- Because trastuzumab was listed in National Reimbursement Drug List in 2017, patients can afford new treatments

---

### Differentiation

- **China breast cancer market is less competitive:** TDM1 not yet launched; Pyrotinib was launched only in mBC
- **Leverage global pivotal trial data** for market approval in China; Subgroup analysis demonstrates similar safety profile and potential better efficacy profile in Chinese
- **Early entry of national reimbursement** with extensive experience in government affairs

---

### CANbridge Development Plan

Bridging study leveraging global trial data for China/Hong Kong/Taiwan NDA submission and approval

---

1 Source: Cancer Statistics in China, 2019; 2 GlobalCAN
Highly Focused Sales Force – Targeting Top Hospitals – NEED to CHECK

Over 80% Herceptin Sales Comes from Top 30% Hospitals¹

Establish 150 FTE commercial team to cover 350+ hospitals 3 yrs after launch; Seasoned commercial management team with extensive experience in China Oncology market

¹ CANbridge estimate
Upcoming Value Creating Milestones

**Rare Diseases**

- **CAN101**
  - 2H 2019 – NDA Submission China
  - 2H 2020 – Commercial Launch China

- **CAN103**
  - 1H 2019 – Select Lead Molecule

- **CAN106**
  - 1H 2019 – Select Lead Molecule
  - 1H 2020 – IND Application
  - 2H 2020 – FIH

- **CAN104/105/107**
  - 2019 – Select Lead Molecules
  - 2020 – IND Application China
  - 2021 – FIH

**Oncology**

- **CAN002**
  - 2018 – Commercial Launch China

- **CAN030**
  - 1H 2019 – NDA submission China/HK/TW
  - 2H 2019 – HK NDA approval
  - 1H 2020 – China NDA approval and TW NDA approval
  - 2H 2020 – Commercial Launch China
Strong Investor Base

Raised total capital of **USD$113m in 3 years**

<table>
<thead>
<tr>
<th>Year</th>
<th>Series</th>
<th>Capital (USD$m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>Series A</td>
<td>5</td>
</tr>
<tr>
<td>2015</td>
<td>Series A+</td>
<td>8</td>
</tr>
<tr>
<td>2017</td>
<td>Series B</td>
<td>24</td>
</tr>
<tr>
<td>2018</td>
<td>CB</td>
<td>30</td>
</tr>
<tr>
<td>2018</td>
<td>Series C</td>
<td>46</td>
</tr>
</tbody>
</table>
Delivering Life-Changing Therapies to Patients

APPENDIX
## CANbridge Board of Directors and Advisors

### Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Position / Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Xue, Ph.D., M.B.A</td>
<td>Chairman and CEO, CANbridge Pharma</td>
</tr>
<tr>
<td>James Zhao, M.D.</td>
<td>Founding Partner, LYFE Capital</td>
</tr>
<tr>
<td>Bing Liu</td>
<td>Founder, CANbridge Pharma</td>
</tr>
<tr>
<td>Wei Cao</td>
<td>Founder, CANbridge Pharma</td>
</tr>
<tr>
<td>Biao Xu</td>
<td>Lead Investor, Jesan Capital Company</td>
</tr>
<tr>
<td>Zhihua Yu</td>
<td>Lead Investor, LongPan Investment</td>
</tr>
<tr>
<td>Ming Li</td>
<td>Vice President, TF Capital</td>
</tr>
<tr>
<td>William Hu</td>
<td>Managing Partner, Qiming Venture Partners</td>
</tr>
<tr>
<td>James A. Geraghty</td>
<td>Board Director, CANbridge Pharma</td>
</tr>
</tbody>
</table>

### Advisors

<table>
<thead>
<tr>
<th>Name</th>
<th>Position / Prior Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Glynn, M.B.A</td>
<td>Synageva (Alexion); Pacific Biosciences; Genzyme; Boston Scientific; Baxter</td>
</tr>
<tr>
<td>James A. Geraghty</td>
<td>Idera Pharmaceuticals; Pieris Pharmaceuticals; Sanofi; Genzyme</td>
</tr>
<tr>
<td>Iain Baird</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Xiaoping Ye, M.D., Ph.D.</td>
<td>TigerMed</td>
</tr>
<tr>
<td>Mark Goldberg, M.D.</td>
<td>Synageva (Alexion); Genzyme; Brigham and Women's Hospital; Dana Farber</td>
</tr>
</tbody>
</table>